Profitable 2-Location Independent Pharmacy — Southern California

Listing Number: 60373-710291

Listing Details

Profitable 2-Location Independent Pharmacy — Southern California
Price: $11,500,000
Location: San Bernardino, California
  • Down Payment: $11,500,000
  • Sales: $9,951,000
  • EBITDA: $2,167,000
  • Inventory: $200,000
  • Furniture, Fixtures, and Equipment: $0
  • Rent: $9,963
  • Employees: 13
  • Year Established: 2018
  • Reason for Selling: Focus on other business

Interested in learning more about this business?

Fill out the form below to gain access to additional information.

Privacy Policy

We are committed to safeguarding the privacy of our website visitors and service users. By checking the opt-in box, you agree to Transworld Business Advisors' Privacy Policy and allow business use of your provided data. Message and Data Rates may apply. Message frequency may vary. You can STOP messaging by sending STOP and get more help by sending HELP. Our full privacy policy can be found here: www.tworld.com/trust

For More Information About This Listing
Tyler Le

Business Description

Highly profitable two-location independent retail pharmacy operating in Orange County and San Bernardino County, California. TTM revenue of $9.95M with $2.17M Adjusted EBITDA (21.8% margin) — independently validated by Plante & Moran, PLLC, a top-15 U.S. CPA firm, as part of a formal Quality of Earnings review. +37% YoY Adjusted EBITDA growth.

Both locations are INSIDE medical office buildings — 6 of the top 10 prescribers practice in the SAME building as our pharmacies. Regional hospital is steps away with shared parking (Orange County). Modern VPN-enabled technology stack for multi-store and enterprise management (PioneerRx PMS, Parata robotic dispensing, Parata Perl verification, AlignRx PSAO, 2D barcode scanning). Business has implemented an AI Automation bot to process prescriptions 24/7 at a fraction of the labor cost. Owner is not active in day-to-day operations; both Pharmacists-in-Charge are long-tenured and highly likely to remain post-close.

Growth catalysts in flight: drive-through expansion under construction at one location (permits pulled, ground broken), 470+ ALF beds in advanced LTC pipeline discussions, Medicare Part B DMEPOS billing infrastructure and Medicare Part B Mass Immunizer active. None of this upside is credited in the listed price — it is available to the buyer.

Transaction: Structured as a Stock Sale (negotiable) at $11,500,000 listed. Real estate leased at both locations (assumable). 1–6 month flexible transition. Full Plante & Moran QoE workbook released post-IOI.